Navigation Links
PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
Date:1/15/2014

9.2 Abbreviations 839.3 Methodology 859.4 Forecasting Methodology 859.4.1 Diagnosed Atopic Dermatitis Patients 869.4.2 Percent Drug-treated Patients 869.4.3 Drugs Included in Each Therapeutic Class 879.4.4 General Pricing Assumptions 879.4.5 Individual Drug Assumptions 889.4.6 Generic Erosion 899.5 Physicians and Specialists Included in this Study 909.6 Primary Research - Prescriber Survey 919.7 About the Authors 929.7.1 Author 929.7.2 Global Head of Healthcare 939.8 About GlobalData 949.9 Disclaimer 94

1.1 List of Tables

Table 1: Symptoms of Atopic Dermatitis 19Table 2: Treatment Guidelines for Atopic Dermatitis 25Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013 27Table 4: Referral Rates to an Indian Dermatologist, Split by Severity and Specialist Type, 2013 28Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in India in 2012 29Table 6: Leading Treatments for Atopic Dermatitis, 2013 33Table 7: Product Profile - Protopic 35Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 36Table 9: Protopic SWOT Analysis, 2013 39Table 10: Product Profile - Elidel 41Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 42Table 12: Elidel SWOT Analysis, 2013 45Table 13: Product Profile - Cyclosporine 47Table 14: Cyclosporine SWOT Analysis, 2013 49Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013 50Table 16: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 52Table 17: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013 59Table 18: Late-Stage Atopic Dermatitis Pipeline, 2013 64Table 19: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013 65Table 20: Phase II and Ph
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Alzheimers Disease - China Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
10. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
11. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that the ... its Data Monitoring Committee's (DMC),review of preliminary ... patients with newly diagnosed multiple myeloma has ... of dexamethasone (Decadron) in,combination with lenalidomide suggests ...
... HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. ... an important,pilot study with a novel synDNA(TM) ... protect against the avian (H5N1),influenza virus. The ... mice treated with the Company's synDNA(TM) vaccine,whereas ...
Cached Medicine Technology:ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ... Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, Rn, ... of Nursing. They will be inducted with Immediate Past ... induction we reported last May. , Our three members ... 2014 American Academy of Nursing Policy Conference in Washington, ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... , TUESDAY, Jan. 17 (HealthDay News) -- Middle-aged men ... risk for atrial fibrillation later in life, researchers say. ... Americans -- is a heart rhythm disorder that can lead ... a known risk factor for atrial fibrillation. Previous research ...
... Centre today performed a minimally invasive surgical procedure to ... first time in Canada. The procedure can significantly reduce ... their hypertension through drugs. These patients, numbering approximately 250,000 ... heart attacks and stroke, which continues to kill thousands ...
... at Kessler Foundation have documented increased cerebral activation ... retraining using the modified Story Memory Technique (mSMT). ... behavioral interventions can have a positive effect on ... validating the clinical utility of cognitive rehabilitation. According ...
... By Kathleen Doheny HealthDay Reporter , ... that target an aggressive type of breast cancer known ... drug alone, researchers report. The dual-drug approach greatly ... cancer by the time a woman was due to ...
... treatment of large tumors, how effective is adoptive T ... answer this question, Dr. Kathleen Anders and Professor Thomas ... (MDC) Berlin-Buch and researchers of the Beckman Research Institute ... California, USA designed and carried out a study comparing ...
... If organisations want to retain qualified nurses they need to ... three key age groups and build on the strong attachment ... key messages to emerge from a large-scale survey of nurses ... Advanced Nursing . Australian researchers surveyed 900 nurses from ...
Cached Medicine News:Health News:'Upper Normal' Blood Pressure Linked to Heart Risk in Men 2Health News:Canada's first renal denervation procedure to reduce high blood pressure performed today 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 3Health News:How immune cells destroy cancer cells - MDC researchers elucidate mechanism 2Health News:Retention study identifies key factors affecting 3 generations of nurses 2Health News:Retention study identifies key factors affecting 3 generations of nurses 3
... ("SES") is a surgical/ mechanical device designed ... of the cornea above Bowman's layer. The ... currently used during LASEK to delaminate the ... and providing a 'minimal-touch' surgical approach, the ...
... The only dedicated, plastic, single use, disposable ... breast needle localization sites, after the needle ... and protruding localization needle from accidental movement ... department to surgery. ,Increase patient confidence in ...
... XLTEK lets you choose how to configure your ... the study to be performed we recommend ... your budget and clinical needs. How do we ... listen. The result? Kortex. The system that lets ...
... The modular AU5400 is a high-volume analyzer ... productivity of the AU5200 analyzer and the ... automates and consolidates chemistry-immuno testing with up ... to 6,600 tests per hour. Choose from ...
Medicine Products: